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Patent ductus arteriosus treatment 
trends and associated morbidities 
in neonates
Joonsik Park, So J Yoon, Jungho Han, In G Song, Joohee Lim, Jeong E Shin, Ho S Eun, 
Kook I Park, Min S Park & Soon M Lee*
To evaluate national epidemiologic data on infants treated for patent ductus arteriosus (PDA) in 
Korea and analyze outcomes associated with different PDA treatments. We retrospectively evaluated 
data on 12,336 patients diagnosed with PDA (International Classification of Diseases-10 code: 
Q250) between 2015 and 2018 from the Health Insurance Review and Assessment database. Among 
them, 1623 patients underwent surgical ligation (code: O1671). We used birth certificate data from 
Statistics Korea to estimate the prevalence, diagnosis, and treatment of PDA. The prevalence of 
infants with PDA was 81 infants per 10,000 live births and 45.2% in very low birth weight (VLBW) 
infants, which increased from 2015 to 2018. PDA ligation was performed in 2571 infants and 22% 
VLBW infants. Medical treatment was administered to 4202 infants, which decreased significantly, 
especially in VLBW infants (62% to 53%). The proportion of treatment was as follows: conservative 
treatment (53.1%), intravenous ibuprofen (24.4%), surgery (20.4%), and oral ibuprofen (10.7%); that 
among 4854 VLBW infants was as follows: intravenous ibuprofen (46.3%), conservative treatment 
(33.2%), surgery (22.2%), and oral ibuprofen (14.2%). Surgical treatment had a significantly higher 
risk (odds ratio 1.36) of mortality than conservative treatment. Surgical and/or medical treatments 
were associated with a higher risk of morbidity. Recently, increased use of conservative management 
of PDA has contributed to improved neonatal outcomes in VLBW infants. Select patients may still 
benefit from surgical ligation following careful consideration.
Patent ductus arteriosus (PDA) occurs in approximately 20-50% of neonates born before 32 weeks gestation and 
in up to 60% of neonates born before 29 weeks  gestation1,2. Because of the possibility of spontaneous closure of 
PDA, the decision whether to treat PDA is still controversial. Treatment options for hemodynamically signifi-
cant PDA (hsPDA) include conservative management, pharmacologic interventions, surgical ligation, and a 
transcatheter approach to ductal closure. However, a consensus on PDA management strategies remains elusive. 
Surgical ligation is usually considered when other medical treatments have either failed or were  contraindicated3.
Recent studies claimed that surgical ligation of PDA is associated with neonatal mortality, short-term morbid-
ity, retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and neurodevelopmental impairment 
in early  childhood4–7. Other studies indicated that treating infants having the most severe symptoms with the 
most aggressive PDA treatments could produce  bias8. There could be confounding effects as suggested by the 
clinical utility of ligation as a rescue treatment for failed medical or conservative treatment. A meta-analysis 
showed that surgical ligation of PDA is associated with reduced mortality, but surviving infants are at an increased 
risk of neurodevelopmental  impairment9. In current neonatal practice, surgical ligation of PDA is still indicated 
for infants with large shunts that cause respiratory insufficiency and whose propensity for spontaneous closure 
appears  low10. The risks and benefits of surgical ligation for PDA compared with those of conservative treatment 
are not fully  understood11.
Prophylactic and early ligation approaches are no longer indicated after a Cochrane Review was published 
in  200812. The trend in PDA treatment strategy in preterm infants has been moving toward adopting a more 
conservative approach rather than treating with aggressive  methods13–18. However, this conservative strategy has 
limitations when treating high-risk patients who need immediate interventions for PDA even though considering 
side effects following its treatment. A wide variation in hospital practices was noted, due to an absence of clear 
evidence of a causal relationship between PDA severity and adverse outcomes to guide management, as well as 
reports of adverse short- and long-term effects from  treatment19.
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Diverse treatment strategies for PDA are still being used, and national epidemiological data can be useful for 
comparing medical outcomes following treatment. Thus, this study aimed to evaluate national epidemiologic 
data on infants treated for PDA in Korea and analyze outcomes associated with different PDA treatments.
Results
The prevalence of infants diagnosed with PDA was 81 infants per 10,000 live births, and the annual prevalence 
rate increased from 70 infants per 10,000 live births in 2015 to 94 infants per 10,000 live births in 2018, especially 
in term infants. The prevalence of PDA diagnosis in very low birth weight (VLBW) infants was 45.2%, which 
increased by 5.6% over the 4 years studied (Table 1). Among 2571 infants treated with surgical ligation, the 
prevalence of surgical ligation by year significantly decreased; 4202 infants were treated with medication, and this 
approach decreased significantly from 2015 to 2018, especially in VLBW infants (62% to 53%). In addition, PDA 
ligation was performed in 23% of infants with a birth weight of 2,500 g or more, 11% of infants with a birth weight 
of 1,500 to 2,500 g, and 22% of infants below a birth weight of 1,500 g. The proportion of small for gestational 
age infants diagnosed with PDA was 4.0% (632 infants) and ranged from 3.8 to 5.9% during the 4 years studied.
The proportion of various treatment methods used in the entire study group and the VLBW subgroup is 
shown in Figure 1. Surgery was performed in 2522 infants (20.4%), IV ibuprofen was administered to 2247 infants 
(24.4%), and 1326 (10.7%) infants were given oral medication. Among 4,854 VLBW infants, 1078 infants (22.2%) 
underwent surgery, 2247 infants (46.3%) were treated with IV ibuprofen, and oral medication was administered 
to 688 (14.2%). Combination therapy involving surgery, IV medication, and oral medication was used in 45 
infants (0.36%) in total and 37 infants (0.76%) in the VLBW subgroup.
Table 1.  Prevalence of PDA Diagnosis, surgical ligation, and pharmacological intervention according to the 
birth weight group. Abbreviations: PDA, patent ductus arteriosus; VLBW, very low birth weight. (% value is 
calculated from denominator of total birth in the relevant year).
2015 2016 2017 2018 Total
Diagnosis of PDA
Number 3,060 3,006 3,213 3,057 12,336
Total (%) 0.7 0.74 0.9 0.94 0.81
Preterm (%) 5.69 5.77 6.74 6.74 6.2
Term (%) 0.33 0.35 0.42 0.45 0.38
 > 2500 g (%) 0.31 0.33 0.4 0.43 0.36
1500-2500 g (%) 2.27 2.50 3.40 3.32 2.84
VLBW (%) 41.69 43.69 48.3 47.25 45.02
Surgical treatment of PDA
Number 671 662 621 568 2,521
Total (%) 21.93 22.02 19.33 18.58 20.44
 > 2500 g (%) 26.37 25.81 20.78 19.01 22.95
1500-2500 g (%) 12.33 13.28 10.56 8.14 10.95
VLBW (%) 19.07 21.88 22.50 23.44 21.67
Medical Treatment of PDA
Number 1,182 1,114 995 911 4,202
Total (%) 38.63 37.06 30.97 29.80 34.06
 > 2500 g (%) 17.71 14.81 10.17 12.09 13.66
1500-2500 g (%) 34.00 31.31 25.64 24.24 28.43
VLBW (%) 61.87 62.66 56.46 52.86 58.57
Figure 1.  Distribution of PDA treatment strategy among the (A) neonate and (B) VLBW infants in Korea.
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The trends in PDA treatment strategy in Korea by year are shown in Figure 2. A conservative approach was 
increasingly popular from 2015 to 2018 while the use of medication or surgical treatment decreased. In the VLBW 
group, the use of conservative treatment also increased, while use of medication alone decreased. However, the 
percentage of infants undergoing surgical treatment remained similar.
Among patients diagnosed with PDA, the mortality rate was 3.5%, which decreased over the years studied 
(3.59% in 2015 to 3.55% in 2018, Figure 3). Among infants treated with surgery, the mortality rate was 3.9%, 
which showed a significantly higher risk (OR 1.36, 95% CI 1.01-1.83, P<0.0001) than conservative treatment. 
The co-morbidities and mortality associated with PDA treatment especially in VLBW infants according to 
the treatment strategy are shown in Table 2. The surgical and medical treatment groups had a higher risk of 
morbidity, including BPD, NEC, and sepsis, than the conservative group. However, the risk of IVH was not 
significantly different compared to that in the conservative treatment group. Medical treatment was associated 
with an increased risk of ROP compared to the conservative treatment; however, surgical treatment showed a 
decreased risk of ROP compared to the conservative treatment.
Discussion
There is still uncertainty and controversy about the management of PDA in preterm infants, resulting in sub-
stantial heterogeneity in clinical practice. There has been a shift in recent years from an aggressive PDA closure 
approach to a more expectant attitude, allowing for spontaneous closure, thus avoiding the need for therapeutic 
interventions. However, the effect of active treatment compared with that of nonintervention remains unclear. 
This study evaluated recent PDA treatment trends and identified related outcomes using nationwide population 
data. Characterizing practice patterns and assessing the relationships between different PDA therapies and their 
health outcomes may provide useful guidance for identifying the best therapies for treating high-risk infants.
From National Health Insurance data in Korea, the prevalence of PDA in VLBW infants was 45%, while the 
prevalence of PDA ligation in VLBW infants was 22%, which was comparable to population studies from the US 
and  Canada4,21,22. From the healthcare insurance dataset of 429,900 VLBW infants in the US from 1998 to 2015, 
Figure 2.  PDA treatment strategy by year among the (A) neonate and (B) VLBW infants in Korea.
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35% of infants were diagnosed with PDA and 18% had undergone PDA  ligation22. From the Canadian Neonatal 
Network (CNN) database in infants under 32 weeks of gestation, 3,673 infants (25%) were diagnosed with PDA 
and 26.4% of those infants had undergone PDA ligation in  20124. In accordance with this study, the study from 
the Korean Neonatal Network, which covers 70% of VLBW infants in  Korea23, reported that 44% received a PDA 
diagnosis and 23% underwent ligation, with 27% of primary ligation between 2013 and 2014.
Several studies in recent decades showed that early PDA treatment had no greater benefit for premature 
infants than alternative supportive  strategies13–18. In US, PDA ligation peaked at 23.7% in 2004 and decreased to 
12.7% in  201522. From the retrospective cohort study of VLBW infants in California, between 2008 and 2014, the 
annual rate of infants undergoing pharmacologic intervention (31% vs 16%) decreased, whereas the proportion 
of infants who were not treated (61% vs 78%) increased. This tendency was also found in the current study. The 
prevalence of treatment in VLBW infants in Korea decreased from 70% to 62% in the VLBW subgroup and that 
of conservative management increased from 30% to 38% during the study period.
However, for moderate-to-large hsPDA, chances of spontaneous closure are rare, and a combination of severe 
symptoms can be found, resulting in more invasive treatments for PDA  closure24. A watchful waiting strategy 
could not be followed in these preterm infants with severe PDA symptoms and they often required immediate 
surgical ligation for rescue therapy. In preterm infants less than 28 weeks gestation, 60-70% of the population 
eventually received medical or surgical therapy for  hsPDA25. In US, PDA ligation still remained around 12.7% 
in  201522. From the cohort in California, infants undergoing primary ligation slightly increased from 2008 to 
2014. In Korea, around 22% of VLBW infants diagnosed with PDA underwent PDA ligation and a similar trend 
was observed between 2015 and 2018. Surgical ligation may remain beneficial in certain populations, such as 
VLBW neonates with unstable vital signs who cannot tolerate conservative managements.
Surgery-related factors may potentially harm infants who undergo  ligation8. Many studies on surgical ligation 
have reported adverse outcomes such as increased  BPD26. Lee et al. retrospectively reviewed data from three 
neonatal intensive care units and identified long-term complications in infants who underwent PDA ligation 
including chronic lung disease in 77%, IVH in 39%, NEC in 26%, and ROP in 28%27. Our national data showed 
more complications in the surgical group than in the conservative strategy group, including increased morbidities 
such as BPD, NEC, and sepsis. In accordance with our study, the CNN has shown a trend of increased morbidi-
ties such as BPD, IVH, NEC, and severe ROP related to PDA  ligation4. However, we assumed that complications 
were not due to the surgery itself but rather because this population was already at a high risk of complications, 
as infants usually underwent ligation after a PDA diagnosis. Notably, there may have been survival bias and 
confounding effects of treatment indication by severity. Patients who underwent treatment for PDA may have 
been experiencing a more severe medical condition, even after correcting for statistical confounders.
The patients with ROP in our data included those with lower stages of the disease (stages 1 and 2), and no 
significant difference in ROP was observed between treatment groups. In contrast, another study observed a 
difference in ROP (>grade 3) in different treatment  groups4.
Several reports about the safety and feasibility of PDA ligation without associated complications suggest 
that early surgical ligation minimizes the adverse effects of hsPDA in preterm neonates who are likely to require 
surgical  treatment28,29. Some studies have shown that ligation is associated with reduced  mortality4. However, 
Table 2.  Risk analysis for the morbidities according to the treatment strategy. Data are shown as number 
(%). Abbreviations: BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; NEC, necrotizing 
enterocolitis; ROP, retinopathy of prematurity; Med, medication; OR, odds ratio; SD, standard deviation.
None Med only
Med + 
surgery Surgery only Risk prediction OR 95% CI
BPD
N=1368 353(22) 630(29) 260(39) 125(31)
Med only vs None 1.46 1.25–1.69
Med + surgery vs None 2.23 1.83–2.71
Surgery only vs None 1.59 1.25–2.03
IVH
N = 982 353(22) 378(17) 148(22) 103(26)
Med only vs None 0.75 0.64–0.88
Med + surgery vs None 1 0.80–1.24
Surgery only vs None 1.22 0.94–1.57
NEC
N = 421 106(7) 175(8) 96(14) 44(11)
Med only vs None 1.24 0.97–1.60
Med + surgery vs None 2.35 1.75–3.15
Surgery only vs None 1.73 1.20–2.51
Sepsis
N = 1274 287(18) 643(30) 247(37) 97(24)
Med only vs None 1.94 1.66–2.27
Med + surgery vs None 2.65 2.17–3.25
Surgery only vs None 1.45 1.12–1.89
ROP
N = 778 237(15) 363(17) 137(20) 41(10)
Med only vs None 1.16 1.01–1.39
Med + surgery vs None 1.47 1.17–1.86
Surgery only vs None 0.65 0.46–0.93
Death
N = 314 119(7) 134(6) 36(5) 25(6)
Med only vs None 0.82 0.64–1.06
Med + surgery vs None 0.71 0.48–1.04
Surgery only vs None 0.83 0.53–1.29
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long-term outcomes remain uncertain due to adverse effects from therapy, higher spontaneous closure rates, 
and smaller ductal shunts with milder symptoms.
We also observed that ORs for some morbidities such as BPD, NEC, sepsis, and ROP were lower in the “only 
surgery” group than in the “medication plus surgery” group in Table 2. Interestingly, the CNN study also found 
more complications with patients who received “both medical and surgical treatment” than “only surgery”  group4. 
This implies that for patients with the most threatening hsPDA, it may be more beneficial to initially treat with 
surgery rather than waiting for failure of the medical treatment. As this trend is only acquired from retrospective 
data, further randomized controlled investigations are needed.
Our study demonstrated a novel finding that early PDA ligation is superior to PDA ligation after the failure 
of medical treatment. The timing of PDA ligation can be also important for determining neonatal  outcomes30. 
Complications related to PDA ligation can be confounded by poor patient characteristics and thus conclusions 
should be interpreted with caution. Treatment should be targeted according to the severity of symptoms to reduce 
adverse effects and less conservative approaches can be justified for select patients.
There are several limitations to this study. There is still no consensus regarding the treatment of PDA and the 
timing of PDA ligation in Korea. Variations in treatment modalities for preterm PDA between clinical units also 
exist. Furthermore, as these data were collected retrospectively, causality between treatment and complications 
cannot be established. Moreover, as the national insurance data rely on only diagnostic codes, detailed medical 
information was limited.
There could be possibilities of interhospital and interpersonal variation due to limited information that hos-
pital and personal identification codes were de-identified to keep personal information protection.
Transcatheter device closure of the PDA in preterm age has recently gaining its popularity in Korea but it 
is only limited in few centers. Statistical efficacy of those next generation treatments needs to be answered by 
future studies.
In conclusion, recent years have shown a trend toward the increased use of conservative management of 
PDA that has contributed to improved neonatal outcomes in VLBW infants. Nonetheless, according to this data, 
surgical ligation seems to be beneficial in select patients following careful consideration. Further study targeted 
at infants requiring surgical intervention will be needed.
Methods
Patients and data source. This study included the data on patients diagnosed with PDA (International 
Classification of Diseases-10 code: Q250) between 2015 and 2018 from their Health Insurance Review and 
Assessment Service (HIRA) claims. (HIRA dataset no. M20190718866). The HIRA database stores the healthcare 
claims of almost all Korean residents. Approximately 98% of patients are covered by the National Health Insur-
ance Service while 2% are covered by medical  aid20. We initially identified 12,336 infants who were diagnosed 
before 6 months of age. We used birth certificate data from Statistics Korea to estimate the prevalence, diagnosis, 
and treatment of PDA (https:// kosis. kr/ stati stics List). The complications associated with PDA included hyaline 
membrane disease, intraventricular hemorrhage (IVH), BPD, necrotizing enterocolitis (NEC), sepsis, ROP, and 
death; this information was obtained from the International Classification of Diseases-10 codes inputted by the 
hospital. Small for gestational age and other information, including gestational age and birth weight, were also 
obtained from the International Classification of Diseases-10 codes in the HIRA database. Medication data 
included intravenous ibuprofen (Pedea® Inj.) and oral ibuprofen. The HIRA database contains the sex, region, 
and payment information for each patient.
Statistical analyses. The baseline characteristics of the subjects were expressed as means and standard 
deviations for continuous variables and as percentages for categorical variables. The cohort was stratified accord-
ing to the gestational age and birth weight or year. Chi-square test was used to compare the neonatal character-
istics and complications between the groups. Logistic regression models were used to determine the significant 
changes in the prevalence of complications, as stratified by the gestational age or birth weight and to obtain odds 
ratios (ORs) and 95% confidence intervals (CIs) for each risk factor associated with mortality and morbidity 
in PDA. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina). 
P-values <0.05 were considered statistically significant.
Ethics statement. In this study, all identifiable variables, including claim-, individual-, and organizational-
level identification numbers, were re-generated randomly by the HIRA database to protect the patients’ pri-
vacy. The study protocol was approved by the Institutional Review Board (IRB) of Gangnam Severance Hospital 
(IRB No. 3-2020-0147). The need for informed consent was waived owing to the retrospective study design and 
approved by the same IRB committee.
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